Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm

Topline Biogen CEO Michel Vounatsos will step down as the company continues to cut about $1 billion in costs annually, Biogen said Tuesday, after Medicare limited coverage for its Alzheimer’s drug, Ad...

Medicare Seeks To Limit Coverage For Controversial Alzheimer’s Drug Aduhelm

Topline The Centers for Medicare and Medicaid Services proposed limiting coverage for Alzheimer’s drug Aduhelm to patients participating in clinical trials Tuesday, after many medical experts claimed ...

Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...

Why Biogen’s Alzheimer’s drug Aduhelm is so controversial

The U.S. Food and Drug Administration’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands o...